Overview
This demonstration study will evaluate the real-world implementation of long-acting cabotegravir (CAB-LA) for HIV pre-exposure prevention (PrEP) through a partnership between the OHSU Tele-PrEP Program (TPP) and the OHSU Home Infusion Pharmacy (HIP). The study will perform a formative evaluation of the TPP/HIP partnership to determine its merit and worth, with revisions made as needed to improve the program, which is reflective of a real-world program rollout. The study is observational, and there is no comparison group. The primary objective is to evaluate adherence to CAB-LA by both urban and rural participants using the TPP/HIP partnership. The goals of the study are improve the TPP/HIP program itself with attention to reducing geographic disparities, and to disseminate best practices and lessons learned to the broader HIV prevention community.
Eligibility
Inclusion Criteria:
- Residence in Oregon
- English or Spanish spoken and written language ability
- Clinical eligibility for PrEP with CAB-LA including HIV-negative serostatus
- Access to stable Internet
- Access to a clean, safe location that is appropriate for home administration
Exclusion Criteria:
- Clinical ineligibility for PrEP with CAB-LA including HIV-positive serostatus, injection drug use as only HIV risk factor, or clinical contraindication (such as a hypersensitivity reaction to CAB-LA or use of a contraindicated medication).
- Uninsured
- Payer does not cover HIP services
- Pregnancy
- Residence outside of the home infusion program's catchment area
- Incarceration
- Decisional impairment